ReSOLUTE

Research empowerment on solute carriers
RESOLUTE logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 10
Grant agreement number
777372

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
12 000 000
EFPIA in kind
11 600 000
Other
250 000
Total Cost
23 850 000

Summary

Transport proteins are the gate-keepers of our cells, effectively controlling the flow of nutrients and other molecules across the cell membrane. With over 400 members, solute carriers represent the largest class of transport proteins. Yet although they have been implicated in diseases ranging from Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) to schizophrenia, solute carriers have never been studied in detail.

The ReSOLUTE project aims to change that, by intensifying research in, and advancing our knowledge of, the solute carrier family. Specifically, the project partners plan to deliver practical research tools, protocols, databases and platforms on solute carriers. The project’s open access ethos means the results will be of benefit to researchers in universities as well as small and large biotech companies worldwide. Ultimately, the project results will aid in the identification of solute carriers that could be used as either drug targets or as pathways for enabling the transport of medicines into specific tissues.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Vifor (International) AG, St. Gallen, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Cemm - Forschungszentrum Fuer Molekulare Medizin GMBH, Vienna, Austria
  • Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev, Munich, Germany
  • Universitat Wien, Vienna, Austria
  • Universiteit Leiden, Leiden, Netherlands
  • University of Oxford, Oxford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Axxam S.A, Bresso (Milan), Italy

CONTACT

Project coordinator
Giulio SUPERTI-FURGA
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
gsuperti[at]cemm.oeaw.ac.at
Project leader
David HEPWORTH
PFIZER
David.Hepworth[at]pfizer.com